Oramed Pharmaceuticals (Oramed Pharmaceuticals) Debt-to-Equity

: 0.32 (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

Oramed Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $51.28 Mil. Oramed Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.34 Mil. Oramed Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $163.82 Mil. Oramed Pharmaceuticals's debt to equity for the quarter that ended in Dec. 2023 was 0.32.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Oramed Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

ORMP' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.01 Max: 0.32
Current: 0.32

During the past 13 years, the highest Debt-to-Equity Ratio of Oramed Pharmaceuticals was 0.32. The lowest was 0.00. And the median was 0.01.

ORMP's Debt-to-Equity is ranked worse than
67.07% of 1072 companies
in the Biotechnology industry
Industry Median: 0.15 vs ORMP: 0.32

Oramed Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Oramed Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oramed Pharmaceuticals Annual Data

Trend

Aug14

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.01

0.32

Oramed Pharmaceuticals Quarterly Data
	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.01	0.01	0.01	0.51	0.32

Competitive Comparison

For the Biotechnology subindustry, Oramed Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oramed Pharmaceuticals Debt-to-Equity Distribution

For the Biotechnology industry and Healthcare sector, Oramed Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Oramed Pharmaceuticals's Debt-to-Equity falls into.

Oramed Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Oramed Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(51.28	+	0.342)	/	163.821
	=	0.32

Oramed Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(51.28	+	0.342)	/	163.821
	=	0.32

Oramed Pharmaceuticals (NAS:ORMP) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Oramed Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Oramed Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Oramed Pharmaceuticals (Oramed Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oramed Pharmaceuticals Inc (NAS:ORMP) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

OJU1:Germany

Address

1185 Avenue of the Americas, Third Floor, New York, NY, USA, 10036

Website

https://www.oramed.com

Oramed Pharmaceuticals Inc is a pharmaceutical company which is engaged in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The ORMD-0801 is a proprietary product which is an orally ingestible insulin capsule for the treatment of diabetes. Its other product includes Oral Glucagon-like peptide-1 which is an incretin hormone, a type of gastrointestinal hormone that stimulates the secretion of insulin from the pancreas.

Executives

Benjamin Shapiro	director	1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
Nadav Kidron	director, 10 percent owner	142 W. 57TH ST., NEW YORK NY 10019
Yadin Rozov	director	9 TERRACE CIRCLE, ARMONK NY 10504
Miriam Kidron	director	2 ELZA STREET, JERUSALEM L3 93706
Michael Rabinowitz	officer: Chief Commercial Officer	1185 AVENUE OF THE AMERICAS, THIRD FLOOR, NEW YORK NY 10036
Arie Mayer	director	MORAN 16, KFAR SABA L3 4428890
Netanel Derovan	officer: Chief Legal Officer	1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
David Silberman	officer: Chief Financial Officer	20 MAMILLA AVENUE, JERUSALEM L3 9414904
Kevin Rakin	director	36 CHURCH LANE, WESTPORT CT 06880
Michael Rabinowitz	officer: Chief Commercial Officer	MAXIM GROUP, LLC, 405 LEXINGTON AVENUE, NEW YORK NY 10174
Leonard Sank	director	3 BLAIR ROAD, CAPE TOWN T3 8005
Gao Xiaoming	director	11F. NO. 266 HANKOU ROAD, HUANGPU DISTRICT, SHANGHAI F4 2000001
Avraham Gabay	officer: CFO, Treasurer and Secretary	2/4 HIGH-TECH PARK, P.O. BOX 39098, JERUSALEM L3 91390
Mark Daniel Hasleton	officer: VP Business Development	13, HIBAT ZION, RAANANA, RAANANA L3 4338111
Aviad Friedman	director	HADASSA 6, TEL AVIV L3 6451306